Highlights BioAtla, Inc.

Equities

BCAB

US09077B1044

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
1.65 ^USD	-5.17%		+8.91%	-32.93%

May. 23	BioAtla, Inc. Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology Annual Meeting	CI
May. 15	Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Key Inflation, Retail Data	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioAtla, Inc. Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology Annual Meeting	May. 23	CI
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Key Inflation, Retail Data	May. 15	MT
BioAtla Shares Jump 10% in Premarket Activity Wednesday as Diluted Net Loss Narrows in Q1	May. 15	MT
BioAtla, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors	May. 06	CI
BioAtla, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Bioatla Hosting Virtual R&D Day to Highlight Ba3071 Cab-Ctla-4 Phase 1 Data in Multiple Solid Tumor Types	Dec. 13	CI
BioAtla, Inc. Presents Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event	Dec. 05	CI
BioAtla, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
BioAtla, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-01	CI
BioAtla, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Viatris Projects Lower 2023 Revenue Despite Swinging to Fourth-Quarter Profit	23-02-27	MT
BioAtla Says US FDA Approves Investigational New Drug Application for BA3182 to Treat Adenocarcinoma	23-02-23	MT
Bioatla Announces FDA Clearance of Investigational New Drug Application for Ba3182, A Cab Epcamxcab-Cd3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma	23-02-23	CI
BioAtla, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
BioAtla : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)	22-08-09	PU
BioAtla, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09	CI
BIOATLA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-05-05	AQ
BioAtla, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-04	CI
BioAtla : Presentation_Needham_FINAL91 - Read-Only.pdf	22-04-11	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BioAtla, Inc.

Equities

BCAB

US09077B1044

Highlights

Filters